Market Overview

Teva Holders Shrug at FDA Approval of Generic-Version of Novartis' TOBI in US

Related TEVA
Benzinga's M&A Chatter for Tuesday November 18, 2014
The Top 25 Analysts On Wall Street
Sofinnova Ventures Closes $500M Fund (Fox Business)
Related NVS
Novartis Int'l Reports Nine New Analyses Show Co.'s LCZ696 Could Avert Course of Heart Failure for Patients
Markets Continue To Rally As The Dow Closes Above 17,000
Bayer Buys Merck Consumer Care Unit (Fox Business)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces today that the U.S. Food and Drug Administration has granted approval of the generic equivalent to TOBI^® (Tobramycin Inhalation Solution USP) in the United States. Pursuant to an agreement with Novartis (NYSE: NVS) on this product, Teva expects to launch this product in late November. Marketed by Novartis, TOBI^® had annual sales of approximately $350 million in the United States, according to IMS data as of June 30, 2013.

Posted-In: News FDA


Related Articles (TEVA + NVS)

Around the Web, We're Loving...

Get Benzinga's Newsletters